ARGNF:OTC-argenx SE (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 383.74

Change

0.00 (0.00)%

Market Cap

USD 23.23B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 564.56B
CMXHF CSL Limited

N/A

USD 89.03B
CSLLY CSL Ltd

N/A

USD 84.45B
UCBJF UCB SA

N/A

USD 25.40B
UCBJY UCB SA ADR

N/A

USD 24.49B
GNMSF Genmab A/S

N/A

USD 18.12B
WXIBF WuXi Biologics

N/A

USD 7.17B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 5.92B

ETFs Containing ARGNF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.43% 61% D- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.43% 61% D- 56% F
Trailing 12 Months  
Capital Gain 8.40% 78% C+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.40% 78% C+ 68% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 26.46% 63% D 70% C-
Dividend Return 26.46% 63% D 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.33% 78% C+ 62% D
Risk Adjusted Return 70.90% 99% N/A 96% N/A
Market Capitalization 23.23B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector